Status:
COMPLETED
Seroprevalence of the Anti-SARS-CoV-2 Antibodies (Causing COVID-19) in Kidney Transplant Recipients in Severely Affected Region
Lead Sponsor:
University Hospital Ostrava
Conditions:
COVID-19 Pandemic
Transplantation, Kidney
Eligibility:
All Genders
18+ years
Brief Summary
Goal of this study is to evaluate the seroprevalence of anti-SARS-CoV-2 antibodies in patients after kidney transplantation who are one of the risk groups for the severe course of the infection and ma...
Detailed Description
The Czech Republic (Central Europe region) is one of the most affected countries in the World by COVID 19 pandemic. By 1st of March 2021, the SARS-COV-2 virus infection was proven in the Czech Republi...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Recipient of a transplanted kidney
- Planned visit to the outpatient nephrology clinic of University Hospital Ostrava, Czech Republic, between 1.5. and 30.7.2021 for enrolment
- Planned blood collection and available results of blood tests from planned inspections from 18.1.2021.
- Signed consent to the use of anonymous data for scientific purposes and publications.
Exclusion
- disagreement with participation in the study and data analysis
Key Trial Info
Start Date :
April 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04874740
Start Date
April 30 2021
End Date
October 30 2022
Last Update
December 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ostrava
Ostrava, Czechia, 70852